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ABSTRACT 
An apparatus for treating a heart of a patient includes a first 
lead and at least a second lead for pacing the heart adapted 
to be in electrical communication with the heart . The appa 
ratus includes a microcontroller in communication with the 
first and second leads which triggers the first lead at either 
different times or the same time from when the microcon 
troller triggers the second lead . Alternatively , the apparatus 
includes a microcontroller in communication with the first 
and second leads that determines heart volume , including 
stroke volume , end - systolic volume , and calculated values 
including ejection fraction , from admittance from signals 
from the first and second leads and uses the admittance as 
feedback to control heart volume ejected , as measured by 
stroke volume , calculated values such as ejection fraction , 
and control end - systolic volume , with respect to the first and 
second leads . A method for treating the heart of a patient . 
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ADMITTANCE MEASUREMENT FOR [ 3 ] Gorcsan J , 3rd , Abraham T , Agler D A , Bax J J , 
TUNING BI - VENTRICULAR PACEMAKERS Derumeaux G , Grimm R A , Martin R , Steinberg J S , 
Sutton M S , Yu C M : Echocardiography for cardiac 
CROSS - REFERENCE TO RELATED resynchronization therapy : recommendations for perfor 
APPLICATIONS 5 mance and reporting — a report from the American Society 
of Echocardiography Dyssynchrony Writing Group 
This application claims priority from U . S . provisional endorsed by the Heart Rhythm Society . J Am Soc 
patent application 61 / 459 , 280 filed on Dec . 10 , 2010 , which Echocardiogr 2008 ; 21 : 191 - 213 . 
is incorporated by reference herein . [ 4 ] Hasan A : How Should Echocardiography Be Used in 10 CRT Optimization ? J Am Soc Echocardiogr 2010 ; 
FIELD OF THE INVENTION 23 : 867 - 871 . [ 5 ] Klimczak A , Chudzik M , Zielinska M , Budzikowski AS , 
The present invention is related to pacing the heart . ( As Lewek J , J K W : Optimization of atrio - ventricular delay in patients with dual - chamber pacemaker . Int J Cardiol used herein , references to the " present invention ” or “ inven 15 2010 ; 141 : 222 - 226 . tion ” relate to exemplary embodiments and not necessarily [ 6 ] Taha N , Zhang J , Ranjan R , Daneshvar S , Castillo E , to every embodiment encompassed by the appended claims . ) Guillen E , Montoya M C , Velasquez G , Naqvi T Z : More specifically the present invention is related to pacing Biventricular pacemaker optimization guided by compre 
the heart by using admittance as feedback to control , such as hensive echocardiography - preliminary observations 
maximize , heart volume ejected , as measured by stroke 20 regarding the effects on systolic and diastolic ventricular 
volume , and calculated values such as ejection fraction , and function and third heart sound . J Am Soc Echocardiogr 
control , such as minimize , end - systolic volume , and / or 2010 ; 23 : 857 - 866 . 
triggering a first lead at different times from when a micro - [ 7 ] Kedia N , Ng K , Apperson - Hansen C , Wang C , Tchou P , 
controller triggers a second lead of a pacemaker . Wilkoff B L , Grimm RA : Usefulness of atrioventricular 
25 delay optimization using Doppler assessment of mitral 
BACKGROUND OF THE INVENTION inflow in patients undergoing cardiac resynchronization 
therapy . Am J Cardiol 2006 ; 98 : 780 - 785 . 
This section is intended to introduce the reader to various The problem with constant rate pacemakers ( and indeed 
aspects of the art that may be related to various aspects of the adaptive pacing ) is that the problem is not closed - loop . That 
present invention . The following discussion is intended to 30 is to say , there is no method for quantifying success con 
provide information to facilitate a better understanding of tinuously in pacing without the need for an expensive doctor 
the present invention . Accordingly , it should be understood visit . This invention will help to close the loop and provide 
that statements in the following discussion are to be read in the best possible pacing algorithm in both bi - v , and normal 
this light , and not as admissions of prior art . pacemakers , also allowing the device to self - calibrate for the 
Heart failure ( HF ) is one of the leading causes of admis - 35 first time . 
sion to the hospital . Studies have shown that patients with The idea of multisite pacing has been shown to improve 
dilated hearts have a reduction in the frequency of hospital outcomes in patients receiving a multi - site pacing device . 
admission and prolongation of life with the implantation of Additionally , optimization of multi - site pacing by maximiz 
bi - ventricular pacemakers and automatic implantable car - ing stroke volume and ejection fraction , and minimizing 
diac defibrillators ( AICDs ) . 2 - 5 These benefits extend to the 40 end - systolic volume , has been shown to improve quality of 
millions of patients with both ischemic and idiopathic car - life in patients using comprehensive echocardiography . 
diomyopathy . Recently , " piggybacking ” technology onto However , proponents of this technology recognize that it is 
AICDs and bi - ventricular pacemakers for sensing the pro - still too time , resource , and labor intensive . The new 
gression of impending heart failure to reduce the number approach described in this invention will allow a measure 
and length of stay of hospital admissions for CHF has been 45 ment of real time stroke volume , end - systolic volume and 
proposed . - 14 ejection fraction coupled to existing bi - ventricular pacing 
Currently , the only way to tell if cardiac output is being leads already implanted within a patient . This new informa 
maximized by a timing algorithm ( or using bi - ventricular tion will allow the use of a self - calibrating algorithm , which 
pacing ) is to use imaging methods such as echocardiography is simple , accurate , and shortens the doctor - patient interac 
which require trips to the hospital , and trained physicians to 50 tion time . A self - calibrating pacemaker timing will outper 
both perform the measurements and interpret results . The form a one - time programmed pacemaker by requiring less 
body of literature shows that pacemaker timing optimization trips to the doctor ' s office for calibration , saving the patient 
improves outcomes in patients , and that there would be time and money , and also has the potential to perform better 
immediate benefit for a new device , which performed this than a normal pacemaker , because it is tailored more closely 
calibration automatically . 55 to the patients needs . 
[ 1 ] Bordachar P , Garrigue S , Reuter S , Hocini M , Kobeissi Regarding alternative technologies which use electric 
A , Gaggini G , Jais P , Haissaguerre M , Clementy J , fields , there are two which have been " piggybacked ” onto 
Hemodynamic assessment of right , left , and biventricular bi - ventricular pacemakers and AICDs that have been tested 
pacing by peak endocardial acceleration and echocardiog - in clinical trials . First , Chronicle? measures right heart 
raphy in patients with end - stage heart failure . Pacing Clin 60 pressures in an attempt to monitor increases that are indica 
Electrophysiol 2000 ; 23 : 1726 - 1730 . tive of heart failure . 6 , 7 , 9 Second , Optivol® and CorVueTM 
[ 2 ] Bordachar P , Labrousse L , Ploux S , Thambo JB , Lafitte use lung conductance measurements as an indication of 
S , Reant P , Jais P , Haissaguerre M , Clementy J , Dos pulmonary edema . 8 , 11 , 12 , 14 However , neither measures LV 
Santos P : Validation of a new noninvasive device for the volume and thus they cannot be used to tune these pacing 
monitoring of peak endocardial acceleration in pigs : 65 devices and maximize LV stroke volume and ejection frac 
implications for optimization of pacing site and configu - tion . More recently Stahl et al . 13 , 1s have proposed generat 
ration . J Cardiovasc Electrophysiol 2008 ; 19 : 725 - 729 . ing an electric field in the RV , and detecting the fringe field 
US 10 , 076 , 669 B2 
from the LV bi - ventricular pacer lead . However , this mea 
surement does not separate the lumped blood and myocar 
dial components . Thus , there are currently no proposed 
technologies that can perform LV blood volume measure - 
ments . 
munication with the heart . There is the step of using the 
admittance as feedback to the microcontroller to control 
heart volume ejected , as measured by stroke volume , cal 
culated values such as ejection fraction , and control end 
5 systolic volume , with respect to the first and second leads . 
BRIEF SUMMARY OF THE INVENTION BRIEF DESCRIPTION OF THE SEVERAL 
VIEWS OF THE DRAWING 
The present invention solves this problem by “ piggyback 
ing ” an admittance measurement system onto bi - ventricular 10 In the accompanying drawings , the preferred embodiment 
and AICD leads , and removing the myocardial contribution of the invention and preferred methods of practicing the 
from the combined electrical blood / muscle signal to deter - invention are illustrated in which : 
mine an increase in LV preload from baseline . Bi - ventricular FIG . la shows a bi - plane left ventriculogram from a 
and RV AICD leads are already located in ideal measure - patient with CHF and a previously implanted AICD / bi 
ment locations — the lateral LV epicardium and the RV apex 15 ventricular pacer demonstrating how the leads span the left 
( FIG . 1a ) . Since blood has 5 times lower resistivity than ventricle ( LV ) blood from the RV apical septum to the lateral 
myocardium , the preferential path for a substantial fraction LV epicardium . 
of the current flow is the LV blood volume ( FIG . 1b ) . The FIG . 1b shows the admittance electric field lines from the 
validity of the present approach was demonstrated by ( a ) RV apical septum to the lateral LV epicardium regarding the 
deriving real - time LV blood conductance signals following 20 apparatus of the present invention . 
instantaneous removal of the myocardial component of the FIG . 2 shows a typical arrangement of three leads con 
signal utilizing epicardial electrodes , ( b ) detecting LV dila sisting of 2 electrodes each . This allows a normal pacemaker 
tion with blood conductance in response to IV Neosyneph - measurement to make 2 ( or more ) separate measurements of 
rine comparable to the standard of endocardial crystals ( see admittance across the heart . 
FIGS . 2 and 3 ) , ( c ) detecting LV dilation with blood con - 25 FIG . 3a shows the effect of Neosynephrine on LVEDV in 
ductance in response to occlusion of the left anterior Epicardial Lead Studies . Note that LV Glood tracks with the 
descending coronary artery , and ( d ) demonstrating that standard of LV Crystal Volume . 
saline placed in the chest cavity to simulate a pleural FIG . 3b shows the same data analyzed without subtracting 
effusion is not a source of artifact in the measurement of the muscle component , demonstrating that dynamic removal 
epicardial admittance . 30 of the myocardial signal using admittance is critical for 
The present invention pertains to an apparatus for treating detecting increasing LV Volume . The pig number is identi 
a heart of a patient . The apparatus comprises a first lead and fied in the legend . There is variation in the absolute volumes 
at least a second lead for pacing the heart adapted to be in in these hearts due to a large variation in porcine size . 
electrical communication with the heart . The apparatus FIG . 4 is a flow chart of feedback loop of present 
comprises a microcontroller in communication with the first 35 invention . 
and second leads which triggers the first lead at either 
different times or the same time from when the microcon DETAILED DESCRIPTION OF THE 
troller triggers the second lead . INVENTION 
The present invention pertains to an apparatus for treating 
a heart of a patient . The apparatus comprises a first lead and 40 Referring now to the drawings wherein like reference 
at least a second lead for pacing the heart adapted to be in numerals refer to similar or identical parts throughout the 
electrical communication with the heart . The apparatus several views , and more specifically to FIG . 1b thereof , there 
comprises a microcontroller in communication with the first is shown an apparatus 10 for treating a heart 16 of a patient . 
and second leads that determines heart volume , including The apparatus 10 comprises a first lead 12 and at least a 
stroke volume , end - systolic volume , and calculated values 45 second lead 14 for pacing the heart 16 adapted to be in 
including ejection fraction , from admittance from signals electrical communication with the heart 16 . The apparatus 
from the first and second leads and uses the admittance as 10 comprises a microcontroller 18 in communication with 
feedback to control heart volume ejected , as measured by the first and second leads 12 , 14 which triggers the first lead 
stroke volume , calculated values such as ejection fraction , 12 at either different times or the same time from when the 
and control end - systolic volume , with respect to the first and 50 microcontroller 18 triggers the second lead 14 . 
second leads . The apparatus 10 may include a pacing circuit 20 in 
The present invention pertains to a method for treating a communication with microcontroller 18 which receives a 
heart of a patient . The method comprises the steps of signal from the microcontroller 18 to activate the pacing 
triggering with a microcontroller a first lead in electrical circuit 20 . The apparatus 10 may include an admittance 
communication with the heart at various times for pacing the 55 circuit 22 which measures volume regarding the heart 16 in 
heart . There is the step of triggering with the microcontroller communication with the microcontroller 18 . The microcon 
a second lead in electrical communication with the heart at troller 18 controls when the admittance circuit 22 measures 
different times than the various times for pacing the heart so volume . The microcontroller 18 determines from the admit 
that the microcontroller triggers the first lead at different tance circuit 22 whether stroke volume , ejection fraction and 
times from when the microcontroller triggers the second 60 end - systolic volume regarding the heart 16 are increasing or 
lead . decreasing over time , and changes the pacing circuit ' s 
The present invention pertains a method for treating the operation to maximize the stroke volume and ejection frac 
heart of a patient . The method comprises the steps of tion and to minimize the end - systolic volume . 
determining heart volume , including stroke volume , calcu - The apparatus 10 may include a pacemaker 30 enclosure 
lated values such as ejection fraction , and end - systolic 65 24 and wherein the admittance circuit 22 is disposed in the 
volume , from admittance with a microcontroller from sig - pacemaker 30 enclosure 24 . The microcontroller 18 may be 
nals from a first lead and a second lead in electrical com - disposed in the enclosure 24 and including a wireless 
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transmitter 26 disposed in the enclosure 24 which transmits The invention will determine which pacing algorithm 
a condition signal indicating whether the heart ' s condition is maximizes patient stroke volume , ejection fraction , and 
getting worse , better or is without change . The pacing circuit minimizing end - systolic volume by cycling through each 
20 may pace each ventricle of the heart 16 separately , where available timing algorithm ( or by changing the timing 
each ventricle is paced separately using a variable time delay 5 between stimulation of each site in a multisite pacemaker 
between a first and a second pace , or takes into account delay 30 ) and measuring the LV volume , and derived stroke 
between atrial pacing and ventricular pacing , or a combina volume , end - systolic volume and ejection fraction for each . tion thereof . The apparatus may include at least a third lead Maximizing the stroke volume in these situations will 15 for multiple admittance measurements adapted to be in directly affect the ejection fraction of the patient , moving the 
electrical communication with the heart . patient into a higher functional NYHA class , and improving The present invention pertains to an apparatus 10 for quality of life both immediately , and over time . treating a heart 16 of a patient . The apparatus 10 comprises In regard to FIG . 1b , a pacemaker 30 ( pacing ) circuit is a first lead 12 and at least a second lead 14 for pacing the well known in the field , and little has been done to change heart 16 adapted to be in electrical communication with the 
heart 16 . The apparatus 10 comprises a microcontroller 18 in 15 its basic design since its invention . However , the method to 
communication with the first and second leads 12 , 14 that control when the pacing circuit 20 fires varies with the type 
determines heart 16 volume , including stroke volume , end - of technology . In the present invention , there are two main 
systolic volume , and calculated values including ejection components : 1 ) a pacing circuit 20 , and 2 ) a volume mea 
fraction , from admittance from signals from the first and surement ( admittance ) circuit . A microcontroller 18 will 
second leads 12 , 14 and uses the admittance as feedback to 20 provide the signal to the pacing circuit 20 to control when 
control heart 16 volume ejected , as measured by stroke each individual pacing site is activated . The microcontroller 
volume , calculated values such as ejection fraction , and 18 will also control when the admittance circuit 22 measures 
control end - systolic volume , with respect to the first and volume . The microcontroller 18 will be able to determine 
second leads 12 , 14 . from the admittance circuit 22 whether the stroke volume , 
The present invention pertains to a method for treating a 25 ejection fraction and end - systolic volume are increasing or 
heart 16 of a patient . The method comprises the steps of decreasing over time , and change the pacing algorithm to 
triggering with a microcontroller 18 a first lead 12 in maximize the stroke volume and ejection fraction , and 
electrical communication with the heart 16 at various times minimizing the end - systolic volume . 
for pacing the heart 16 . There is the step of triggering with Further , the microcontroller 18 will signal process the 
the microcontroller 18 a second lead 14 in electrical com - 30 results from the admittance circuit 22 within the pacemaker 
munication with the heart 16 at different times than the 30 enclosure , and then a signal indicating whether the 
various times for pacing the heart 16 so that the microcon - patient condition is getting worse , better , or staying the same 
troller 18 triggers the first lead 12 at different times from can be sent to the receiver 28 using the wireless transmitter 
when the microcontroller 18 triggers the second lead 14 . 26 . No extra processing will be necessary external to the 
There may be the step of determining stroke volume , and 35 implanted device , although , if desired , the processing of the 
systolic volume , and ejection fraction of the heart 16 using data could occur outside of the patient in an alternative 
epicardial admittance . There may be the step of pacing the embodiment . 
heart 16 by separately pacing each ventricle of the heart 16 For 4 electrodes to measure admittance , only one pro 
using a variable time delay between a first and a second cessing circuit ( admittance circuit 22 w / current source ) is 
pace , or by taking into account delay between atrial pacing 40 necessary . An additional embodiment of the current inven 
and ventricular pacing , or by a combination thereof . There t ion is for multiple admittance circuits to measure the 
may be the step of re - measuring stroke filing , and systolic volume of the LV from different locations , or for one 
volume , and ejection fraction after changing how the heart admittance circuit to measure multiple locations in 
16 is paced . There may be the step of comparing the sequence . This redundancy can be used to increase accuracy 
determining step and the re - measuring step , and repeating 45 in situations where implantation of the leads in their ideal 
them until the stroke volume and ejection fraction are locations is not possible . 
maximal , and end - systolic volume is minimal . Adaptive Pacing Algorithms 
The present invention pertains to a method for treating the The key method for determining if a pacing algorithm is 
heart 16 of a patient . The method comprises the steps of working correctly should be dependent on how effectively 
determining heart 16 volume , including stroke volume , 50 the heart 16 is pumping blood . Maximum effectiveness is 
calculated values such as ejection fraction , and end - systolic therefore equivalent to maximum cardiac output . 
volume , from admittance with a microcontroller 18 from Algorithm : 
signals from a first lead 12 and a second lead 14 in electrical 1 . Determine stroke volume , end systolic volume , and 
communication with the heart 16 . There is the step of using ejection fraction using epicardial admittance . 
the admittance as feedback to the microcontroller 18 to 55 2 . Pace the heart 16 using either : 
control heart 16 volume ejected , as measured by stroke a . A well known pacing method ( see pacing “ algo 
volume , calculated values such as ejection fraction , and rithm ” method guide by Bernstein et al . , Journal of 
control end - systolic volume , with respect to the first and Pacing and Clinical Electrophysiology , Volume 25 , 
second leads 12 , 14 . No . 2 , February 2002 ) . 
In the operation of the invention , the key elements of this 60 b . A bi - ventricular pacing algorithm where each ven 
invention include 1 ) the use of an epicardial admittance tricle is paced separately using a variable time delay 
measurement to determine improvements in stroke volume between the first and the second pace . 
and / or end systolic volume , and 2 ) the ability of this C . A pacing method that takes into account delay 
information to determine the best possible pacing algorithm between atrial pacing and ventricular pacing . 
to use based on which algorithm maximizes patient stroke 65 d . Some combination of the above 
volume , ejection fraction , and minimizes end - systolic vol . 3 . Measure stroke volume , end systolic volume , and 
ume from the first element . ejection fraction after changing algorithm . 
US 10 , 076 , 669 B2 
5 30 is : 
4 . Compare step 3 with step 1 and repeat 2 - 4 until the save , money , and time for all involved , reducing greatly the 
stroke volume and ejection fraction are maximal , and amount of time between the patient ' s onset of disease and 
end - systolic volume is minimal . treatment . 
Pacing methods ( sometimes called “ algorithms ” by the What will be new and in the enclosure of the pacemaker 
medical community ) : 
1 . Well - known pacing algorithms such as those described 1 . Microcontroller 18 programming or an equivalent 
in Bernstein et al . are often chosen for a patient at the decision making circuit which provides feedback based on 
time of implantation . However , there is no guarantee whether stroke volume and EF have been maximized , and 
that the patient will not benefit from a changing pacing ESV minimized . A variety of well known control algorithms 
algorithm depending on their activity , long - term health 10 can be used here , and their application is we can be used here , and their application is well known to one 
status , or other factors . Switching between these well skilled in the art . The new feedback loop with the decision known pacing algorithms could provide both short making process is shown in FIG . 4 . 
term benefit ( such as when exercising ) , and long - term 2 . The admittance circuit 22 , is described in U . S . patent benefit ( such as improved cardiac remodeling ) . application Ser . No . 12 / 657 , 832 , incorporated by reference 
Because the microcontroller 18 is in direct contact with 15 herein , but minimized to fit into the size of a pacemaker 30 
the pacing unit , switching algorithms is a matter of enclosure . The miniaturization may be achieved by putting outputting a different pacing pattern to the pacing unit . the entire admittance circuit 22 onto a chip if desired . See The specific event that will trigger a switch in pacing is U . S . patent application Ser . No . 121657 , 832 , incorporated by dropping below an adaptive threshold for cardiac out reference herein . Such circuits can be made small enough 
put . Over time , if the patient improves , the threshold for 20 without placement on a chip if desired . 
aggressive therapy may be changed . This adaptive 3 . An additional pacing circuit 20 is installed in the case 
nature of the threshold for treatment allows the pacer to where each lead in a bi - ventricular pacemaker 30 will be 
adapt to changes that occur over a long time span . paced independently . This only mildly increases complexity . 
Cardiac output , stroke volume , ejection fraction and Basically , there would be 2 of the flow charts in parallel , 
end - systolic volume are measured using the admittance 25 delivering pacing pulses at different times . The end result 
system directly . Therefore , if cardiac output , stroke and control algorithm are still the same . 
volume , and ejection fraction start to go down , at some 4 . Optionally , any known pacemaker configuration could 
threshold ( much like Optivol from Medtronic ) , the benefit from this design , with various lead implant locations . 
pacing algorithm will be switched to maximize the However . nothing external to the pacemaker enclosure 
cardiac output , stroke volume and ejection fraction 30 would need to change . 
again . Other currently deployed applications which do Calculation Theory and Epicardial Blood Conductance 
not use hemodynamic variables include accelerometers Measurement 
within the pacemaker 30 to determine that increased Conductance measurements have been available as an 
patient motion is present and hence higher demand is invasive tool to detect instantaneous LV volume since necessary for more rapid pacing . 35 1981 . 23 Tetrapolar electrodes are usually placed on a cath 
2 . It is possible to pace the heart 16 using leads in both the eter located within the LV chamber to determine instanta coronary veins ( LV lead ) and in the RV apex ( RV lead ) . neous volume by electrical conductance measurement . Con 
If the LV lead is paced separately from the RV lead , a ductance systems generate an electric field using a current 
nonzero time delay between the LV lead and the RV source , and volume is determined from the instantaneous lead could produce a better cardiac output , stroke 40 returning voltage signal . Conductance is the preferred mea 
volume ( SV ) , and ejection fraction ( EF ) than has been surement over resistance ( or impedance ) because it has a 
previously discussed using bi - ventricular pacing ( such direct ( not inverse ) relationship with volume . Conductance as Cardiac Resynchronization Therapy devices ) . Pac electrodes have not been previously placed on the LV 
ing separately is a matter of having multiple pacing epicardium to interrogate the LV blood volume , as done in 
circuits controlled by a microcontroller 18 . There are 45 the current invention . 
already microcontrollers present within most current The relationship between measured blood conductance 
pacemakers . This measurement can be performed using and LV blood volume is determined primarily by the shape a microcontroller 18 and multiple pacemakers , or mul of the current field in the blood pool and surrounding tiple pacing circuits connected one per electrode . myocardium . For example , in a uniform electric field 
Atrio - ventricular delay is often set at the time of pace - 50 a Atrio - ventricular delay is often set at the time of pace - 50 approximation the measured time - dependent resistance , 
maker 30 implantation to maximize stroke volume and EF , Rblood is proportional to the electrode separation distance , 
and minimize end - systolic volume ( ESV ) . This type of L ( t ) , and inversely proportional to the cross - sectional area of pacing is currently beneficial to the patient , but it requires a the field , A ( t ) ; and the converse for the measured blood doctor ' s visit to change the timing delay between atria and conductance , Gblood , where p is blood resistivity : ventricle . Real - time feedback from epicardial Admittance 55 
can address this problem in real time , like the previous two 
pacing methods . With the power of the feedback loop and a 
microcontroller 18 in the pacemaker 30 , a doctor ' s visit will Rblood = A ( T ) 
not be necessary . Doctors tune pacemakers using the same A ( 1 ) 
process outlined in the algorithm . They measure the volume 60 Gblood = PL ( 1 ) of the heart 16 ( usually using an echo machine ) , change the 
pacing algorithm ( usually using the help of a clinical engi 
neer ) , and they re - test the volume of the heart 16 ( using Some of the measurement electrode positions will pro 
another echo ) . The patient visit , doctor , and engineer are not duce a blood conductance primarily sensitive to the cross 
necessary if the microcontroller 18 implanted within the 65 sectional area change while others are primarily sensitive to 
pacemaker 30 makes these decisions in real time as the the separation distance . As the cross - sectional area of the LV 
patient ' s heart 16 is changing volume over time . This will increases , there is a corresponding increase in blood con 
PLt )
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ductance . Thus , for the purposes of the current invention , Protocol 
area - dependent electrode configurations only were focused This invention was conducted in compliance with the 
on . United States Food and Drug Administration ( FDA ) Good 
Dynamic Muscle Conductance Removal Laboratory Practices Regulations ( 21 CFR Part 58 ) , follow 
Epicardial admittance is a measurement taken in the 5 ing approval of the animal use committee at the University 
complex plane , and has both a magnitude , ?Y? ( Siemens ) and of Texas Health Science Center San Antonio . For n = 15 
a phase , LY ( degrees ) . The values for admittance are a Yorkshire Pigs studied , the body weight ranged from 42 kg 
combination of both the muscle and blood conductance , and to 78 kg ( mean = 60 = 12 . 6 kg ) , 14 were male and 1 was 
the muscle susceptance ( WC ) , for both are present in the female . Pigs were sedated with Telazol 4 mg / kg IM , intu 
current field . The process for separating admittance into " bated and anesthesia was maintained with 1 - 2 % Isoflurane 
blood and muscle conductance was outlined previously for with 100 % oxygen . The right neck was dissected to gain 
the case of a tetrapolar catheter where the blood and muscle access to the jugular vein and carotid artery . A sternotomy 
are in parallel . 17 However , there is no previously proposed was performed and the pericardium was partially opened . 
model for the separation of blood and muscle components of 16 Amiodarone 150 mg IV was given over 30 min , and repeated 
a cross - chamber epicardial admittance measurement , where 30 min later . Following loading of Amiodarone , a Lidocaine 
the blood and muscle components are in series . This new infusion was initiated at 1 ug / min for the remainder of the 
theory to separate blood and muscle components is pre protocol . Although there was anticipated myocardial depres 
sented below . sion from this approach , there was greater concern that the 
20 porcine model has a low ventricular fibrillation threshold . 
Instrumentation 
Platinum - Platinum black electrodes were chosen for the 
experiment because of their low electrode interface imped 
ance ( Medtronic , Minneapolis , Minn . ) . Electrode locations 
25 were chosen to simulate the approximate positions of an RV 
Rp = Re { z } - - AICD endocardial lead , and the bi - ventricular lead on the 
lateral LV epicardium . Two sets of 4 electrodes spaced 1 cm 
apart were sewn onto a felt backing , and each were sewn 
onto the LV epicardium . The anterior electrodes were sewn 
Where R , , is the resistance of muscle ( 2 ) , and R , is the 30 parallel to the distal LAD to simulate the RV AICD lead , and 
resistance of blood ( 2 ) , Em is the permittivity of muscle the posterior electrodes were sewn parallel to a left marginal 
( F / m ) , and one is the conductivity of muscle ( S / m ) . The vein to simulate the bi - ventricular lead . Electrode pairs were chosen for a cross - ventricular chamber tetrapolar measure complex impedance Ž can be separated into real ( Re { Z } ) ment with a current producing and a voltage - sensing elec 
and imaginary parts ( Im { Z } ) . The properties of the myo - 35 trode on both the anterior and the posterior epicardium . 
cardium on , and am can be calculated using a surface probe The pigs were also instrumented with two dimensional 
measurement . 17 , 19 In an epicardial measurement the field endocardial crystals as outlined above , a left carotid pressure 
generated is mostly transverse , while in a surface probe sensor ( 3F , Scisense , London , ON ) , a 6F sheath in the 
measurement ( and in a traditional LV catheter measure - jugular vein , an RV pressure sensor ( inserted directly 
ment ) , the field is mostly longitudinal . This difference has 40 through the anterior RV wall ( 1 . 2 F , Scisense , London , ON ) , 
been measured by others , and was corrected in the data by a descending thoracic saline filled balloon occluder ( 16 or 18 
multiplying by a factor of 2 . 24 , 25 The penetration depth for mm diameter , In Vivo Metric , Healdsburg , Calif . ) to gener 
the surface probe used to measure the porcine myocardial ate transient occlusion as an alternative method to produce LV dilation , and an aortic flow probe , which was placed in properties was 3 . 6 mm , which does not extend into the LV 45 45 the descending thoracic aorta ( Transonic , Ithaca , N . Y . ) blood volume beneath . immediately distal to the balloon occluder to document that LV Volume Measurement with 2 Dimensional Sonomi 11 - occlusion was obtained . crometry Properties Measurement and Hematocrit 
The standard of volume measurement used to validate this An epicardial probe was applied to the surface of the 
invention is two dimensional ( 2D ) sonomicrometry ( endo - 50 intact beating open - chest heart . The stimulus current was 
cardial ) crystals . 2D endocardial crystals is an acceptable generated using the instrumentation previously described . 29 alternative to 3D echocardiography in large animal hearts 
when the two short axes are equal in distance , 26 - 28 and this Real - time IYI and LY were measured and myocardial 
distance is maintained during acute LV dilation . Addition permittivity ( Em ) and conductivity ( om ) were calculated as 
ally , the porcine myocardium is prone to arrhythmias , and 55 and as described previously . 19 Briefly , the surface probe " cell con 
there is significant trauma associated with placing the third stant ” , k ( m ) , determined in saline of known electrical 
crystal plane through the septum . Consequently , 2D endo conductivity , is used to calculate : Om = kxGm and em = kxCm , 
cardial crystals are the practical approach . The two dimen where Gm = Re { Y } and Cm = Im { Y } / 22 and w = 2af , where kis 
sions measured included the anterior - posterior and apex - the cell constant of the probe used ( 1 / m ) , G , is the conduc 
base planes via pairs of 2 mm piezo - electric ultrasonic 60 tance of muscle ( S ) , C , is the capacitance of the muscle , and 
transducers positioned on the endocardial surface through a f is the frequency of excitation ( Hz ) . Hematocrit was deter 
stab wound through the LV myocardium and secured with a mined both at baseline and at the end of the experiment via 
purse - string suture . The two crystal pairs were attached to a capillary tubes and a Clay Adams Readacrit centrifuge 
digital sonomicrometer ( Sonometrics Corporation , London , ( model CT - 3400 , Becton Dickinson , Sparks , Md . ) . Whole 
Ontario , Canada ) and the digital output was then trans - 65 blood samples were spun for 5 minutes at 8 , 500 rpm , and the 
formed into volume by fitting the points to a prolate ellip - volume of packed red cells was expressed as a percentage of 
soid . 26 , 28 total volume . 
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Neosynephrine ( Phenylephrine ) for LV Dilatation metric autocorrelation matrix and fixed intercepts for each 
Neosynephrine was chosen to increase afterload and pig and vector . The significance of the relation between 
secondarily dilate the LV in a dose - response fashion to blood conductance and crystal volume was assessed using a 
simulate LV dilation as would occur in a heart failure Wald statistic for testing the null hypothesis that the coef 
patient . Neosynephrine was infused at a constant rate of 75 , 5 ficient of LV blood conductance in the repeated measures 
150 , and 300 ug / min in the first n = 2 pigs . For the later n = 9 linear model is zero . Statistical testing was two - sided with a 
pigs , a lower dose of 37 . 5 ug / min was added to this same significance level of 5 % using SAS Version 9 . 2 for Windows 
infusion protocol . Baseline and data from at least 2 doses of ( SAS Institute , Cary , N . C . ) . For LAD occlusion , transient 
Neosynephrine where LV dilation occurred as defined by Ao occlusion , and pleural effusion simulation , paired base 
endocardial crystals , were required for data to be used in " line and intervention data were compared using a Student ' s 
analysis . Some doses of Neosynephrine did not result in LV t test , again with a level of significance of 5 % . All results are 
dilation and this varied in every pig . Thus , the doses given reported as mean standard deviation . 
in the results section are the baseline , and mean low and high Results 
doses of Neosynephrine that achieved LV dilation . Each 
dose of Neosynephrine was infused for 10 minutes to The mean systolic aortic pressure was 80 - 13 mmHg , and 
achieve steady state , and then data were acquired over the the heart rate was 86 - 17 bpm . The mean LV end diastolic 
subsequent 5 minutes for a total of 15 minutes per dose . and end systolic long axis by crystals was 82 + 6 and 74 + 5 
Data acquired included heart rate , carotid pressure ( AOP ) , cm , respectively ; and the mean LV end diastolic and end descending thoracic aortic flow ( Ao Flow ) , short and long 30 short and long 20 systolic short axis by crystals was 47 + 4 and 40 + 4 cm , axis endocardial crystals , epicardial impedance magnitude ( 1 = respectively . The calculated mean LV EDV was 100 + 31 mL , 
ZI ) and phase angle ( LZ ) . Data were acquired while the and the mean LV ESV was 69 + 25 mL measured via endo 
respirator was suspended at end - expiration for at least 5 cardial crystals . The mean LVEF was 31 : 6 % , consistent 
cardiac cycles . with a depressed but non - dilated LV preparation from the 
Alternative Methods for LV Dilatation 25 anesthetics and amiodarone given to minimize ventricular 
To determine if LV dilation could be detected by epicar - fibrillation . The mean descending thoracic flow was 8 . 0 - 1 . 8 
dial admittance , two additional preparations were exam - L / min , and the mean RV systolic pressure was 19 + 3 mm Hg . 
ined - acute LAD occlusion and transient aortic occlusion . Hematocrit at the initiation of the protocol was 
LAD Occlusion 30 . 0 + 2 . 3 % , and at the end of the protocol 33 . 0 + 4 . 7 % , 
A suture was placed under the middle LAD , proximal to 30 consistent with hemo - concentration due to minimal fluid 
the epicardial admittance electrodes , and tied off to produce administration during the protocol to mitigate changes in 
an acute dilation of the middle and distal anterior myocar blood and myocardial electrical properties as a source of 
dium . Data obtained were identical to the Neosynephrine artifact . The mean distance from the LV apex to the most 
protocol . Due to ventricular fibrillation , complete data were apical epicardial admittance electrode on the anterior surface 
only obtained in n = 6 porcine studies . 35 was 3 . 0 + 0 . 9 cm , and on the posterior surface was 3 . 0 - 0 . 5 
Transient Aortic Occlusion cm , consistent with the admittance electrodes being parallel 
Transient aortic occlusion was performed successfully in to one another on either side of the LV epicardium . 
n = 11 pigs . Occlusion was controlled by the introduction of The end diastolic and end systolic epicardial LV admit 
saline into the occluder , and successful occlusion was tance magnitudes = 1 / 1 ZI ) were 15 . 8 + 2 . 0 and 14 . 5 + 1 . 9 ms . 
defined by the reduction of descending thoracic aortic flow 40 
to less than 1 L / min . The flow probe was always immedi respectively ; and the mean phase angles ( Y = - ZZ ) were 9 . 2 + 3 . 0 and 7 . 4 + 3 . 2 degrees , respectively . ately distal to the balloon occluder . 
Pleural Effusion Simulation Properties Summary 
Pleural effusions are common in heart failure patients , and Myocardial properties were determined in each pig for 
are a common source of artifact in the measurement of lung 45 use in the equations to separate the blood and muscle 
conductance by systems such as OptivolTM8 , ll , 14 and admittance as published previously . 19 The myocardial con 
CorVueTM , since the electrical fields generated by these ductivity was tm = 0 . 33 + 0 . 03 S / m , the myocardial permittiv 
devices extend into the lungs . Epicardial admittance gener ity was Em = ( 19710 + 2786 ) * € , F / m , and the calculated ratio 
ates an electric field , which extends across the LV and thus of a / E for myocardium was 1 , 923 , 320 : 179 , 592 S / F . 
should not have this source of artifact . To test this hypoth - 50 Neosynephrine for LV Dilatation 
esis , the chest cavity was filled with saline during the Data from n = 11 porcine studies is shown in FIG . 3 . The 
measurement of LV epicardial admittance ( both on the right low dose Neo was 90 : 54 ug / min , the high dose Neo was 
and left sides of the heart ) . The pericardium was used as a 180 = 107 ug / min . The blood conductance was computed 
sling to keep the saline from coming into direct contact with from the epicardial impedance ( IZI ) and phase angle ( LZ ) , 
the electrodes , similar to the final implementation of epi - 55 and plotted against LV volume calculated from endocardial 
cardial admittance . Immediately after baseline measure crystals . LV end - diastolic volume ( EDV ) and complex 
ments as outlined above , saline of conductivity close to impedance at end diastole were measured in each pig and the 
blood ( 7941 – 124 uS / cm ) was introduced into the chest . The results were converted into the conductance of blood ( LV 
introduced volume for n = 7 pigs was 425 - 90 mL , and Good ) using the admittance technique , removing muscle 
following introduction all measurements were repeated . 60 contribution in real time ( FIG . 3A ) . The conductance of 
Data Analysis blood ( Gblood ) , expressed in milli - Siemens ( ms ) , and LV 
The slope relating blood conductance ( ms ) and endocar - volume ( V ) , expressed in milliliters ( mL ) , were measured at 
dial crystal volume ( mL ) was determined in 11 animals at up multiple values of LV volume for between 1 and 6 vectors 
to three doses of Neosynephrine in each of up to 6 vectors , on each pigs and the within - animal mean slope was com 
yielding a total of 99 paired measures of blood conductance 65 puted for FIG . 3A . The slope relating Good ( ms ) and the 
and crystal volume ( FIG . 3 ) . Data were analyzed based on adjusted volume ( mL ) , 1 . 16 + 0 . 48 mS / mL , was significantly 
a repeated measures linear model with a compound sym different from zero ( p = 0 . 017 ) . Data were also analyzed 
Un 
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using the traditional conductance technique , which does not sensitivity of the admittance technique is due to the use of 
remove muscle contribution and demonstrates that the abil a phase measurement in the calculation of the admittance , 
ity to detect LV dilation was lost and is dependent upon which allows the real - time separation of blood and muscle 
having access to the imaginary component of the myocardial components . The high resistance of muscle normally 
signal ( FIG . 3B ) . swamps a measurement of blood and muscle in series , 
LAD Occlusion for LV Dilatation because the resistivity of muscle is nearly 5 times that of Hemodynamic parameters are shown in Table 1 at base blood . This causes the total measured traditional conduc 
line and following LAD occlusion . Acute LAD occlusion tance signal to be low and non - specific ( FIG . 3B ) when produced a significant decrease in aortic pressure and flow . compared to the LV blood conductance determined using The anticipated increase in LV volume was detected by both 10 admittance ( FIG . 3A ) . the standard ( endocardial crystals ) as well as blood conduc In contradiction , studies by Stahl et al . 13 , 15 using tradi tance . The large standard deviations in the blood conduc 
tance are a result of the wide range of electrode positions , tional conductance have shown promise in the detection of LV dilation using existing bi - ventricular leads . Stahl ' s and an offset , which may be caused by variable surface 
electrode - myocardium contact . On average , an increase of 15 IV 15 invention is very different from the current invention for two 
17 % from baseline LV blood conductance corresponded to reasons . The first major difference is that the stimulating 
an LV volume increase of 4 % . electrodes span the LV , while in Stahl ’ s they reside com 
Transient Ao Occlusion pletely within the RV . In Stahl ' s design , the majority of 
Hemodynamic parameters are shown in Table 2 at base current will be confined to the RV because the resistivity of 
line and peak transient Ao occlusion . AOP and endocardial 20 muscle is 5 times higher than blood . This limitation is 
crystal derived LV volume both increase . Ao flow decreased overcome in the current invention by forcing the current 
below 1 L / min since that was the definition for a successful across the LV by maintaining the excitation and sink elec 
aortic occlusion . The increased afterload increases the LV trodes on opposite sides of the LV . The preferential path for 
blood conductance by 7 % , and the crystal LV volume by 9 % . current is therefore the low resistivity blood pool . The 
Pleural Effusion Simulation 25 second major difference is that the current invention 
Hemodynamic parameters are shown in Table 3 at base - employs complex admittance for determining the relative 
line and pleural effusion simulation . Neither the LV blood muscle contribution to the measured signal . As seen in FIG . 
conductance nor the crystal derived LV volume changed 3 , this separation of blood from muscle provides increased 
with saline placed around the heart 16 . sensitivity to heart failure detection ( increasing LV preload ) . 
This invention has demonstrated that LV blood conduc - 30 The present invention represents the first evidence that a 
tance can be determined from the epicardial position , despite cross - chamber complex admittance measurement shows 
the current generating and sensing electrodes being in con - improved sensitivity to LV blood pool volume measurement 
stant motion with the heart 16 , and with dynamic removal of over a traditional conductance ( or resistance ) measurement . 
the myocardial component of the returning voltage signal . In summary , a new electrical approach has been devel 
Specifically , it has been demonstrated that ( a ) a physiologic 35 Oped which can detect LV volume , taking advantage of 
LV blood conductance signal can be derived , ( b ) LV dilation pre - existing AICD and bi - ventricular pacing lead locations , 
in response to dose - response iv Neosynephrine can be and maturing the conductance approach to moving source 
detected by blood conductance in a similar fashion to the and sensing electrodes while instantaneously removing the 
standard of endocardial crystals when admittance is used , myocardial component to generate a final LV blood conduc 
but not when only traditional conductance is used , ( c ) the 40 tance signal . 
physiologic impact of acute LAD occlusion can be detected References , all of which are incorporated by reference 
by blood conductance as LV dilation , and ( d ) a pleural herein . 
effusion simulated by placing saline outside the pericardium [ 1 ] Bleumink G S , Knetsch A M , Sturkenboom MC , Straus 
do not serve as a source of artifact for blood conductance S M , Hofman A , Deckers JW , Witteman J C , Stricker B 
measurements . 45 H : Quantifying the heart failure epidemic : prevalence , 
Pleural effusions are frequent findings in patients with incidence rate , lifetime risk and prognosis of heart failure 
advanced heart failure . Devices which interrogate the lungs The Rotterdam Study . Eur Heart J 2004 ; 25 : 1614 - 1619 . 
for pulmonary edema use a trans - thoracic resistance mea - [ 2 ] Bardy G H , Lee K L , Mark D B , Poole J E , Packer DL , 
surement from the tip of the RV AICD lead to the case of the Boineau R , Domanski M , Troutman C , Anderson J , John 
battery pack for the pacemaker / defibrillator , and thus pro - 50 son G , McNulty S E , Clapp - Channing N , Davidson - Ray 
vide a wide electric field including the LV , left atrium , L D , Fraulo ES , Fishbein DP , Luceri R M , Ip J H : 
thoracic skeletal muscle , ipsilateral lung tissue , intravascular Amiodarone or an implantable cardioverter - defibrillator 
blood volume in the lung , pulmonary interstitial edema and for congestive heart failure . N Engl J Med 2005 ; 352 : 
finally pleural effusions to measure a changing fluid index . 225 - 237 . 
Having an electrical approach that is focused on the LV 55 [ 3 ] Bristow MR , Saxon L A , Boehmer J , Krueger S , Kass 
myocardium and blood volume would be preferable , but DA , De Marco T , Carson P , DiCarlo L , DeMets D , White 
there still exists some electrical field extension into other B G , DeVries D W , Feldman A M : Cardiac - resynchroni 
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whether epicardial admittance would artifactually detect in advanced chronic heart failure . N Engl J Med 2004 ; 
pleural effusions , fluid was placed outside the pericardium in 60 350 : 2140 - 2150 . 
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traditional conductance does not ( FIG . 3B ) . This increased Andrews ML : Prophylactic implantation of a defibrillator 
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[ 31 ] Braunwald E : Braunwald ' s Heart Disease . A Textbook The invention claimed is : 
of Cardiovascular Medicine Saunders ( Elsevier ) , 2005 , 1 . An apparatus for treating a heart of a patient compris 
pp . 540 . 
[ 32 ] Baan J , Jong TTA , Kerkhof PL M , Moene RJ , Vandijk a pacemaker enclosure having : 
AD . Vandervelde E T . Koops J : Continuous Stroke 5 a first existing lead and at least a second existing lead for 
Volume and Cardiac - Output from Intraventricular Dimen pacing the heart adapted to be in electrical communi 
sions Obtained with Impedance Catheter . Cardiovascular cation with the heart ; 
Research 1981 ; 15 : 328 - 334 . a microcontroller in communication with the first and 
[ 33 ] Baan J , Vandervelde E T , Debruin HG , Smeenk G J , second leads which triggers the first lead as a function of epicardial admittance in real time at either different Koops J , Vandijk A D , Temmerman D , Senden J , Buis B : 10 times or a same time from when the microcontroller Continuous Measurement of Left - Ventricular Volume in triggers the second lead for pacing the heart and takes Animals and Humans by Conductance Catheter . Circula into account delay between atrial pacing and ventricu tion 1984 ; 70 : 812 - 823 . lar pacing , where the admittance is a combination of Tables both muscle and blood conductance and muscle sus 
ceptance components , where the blood and muscle TABLE 1 components are in series and the admittance has both a 
LAD Occlusion . real part and an imaginary part ; 
a pacing circuit in communication with the microcon 
Baseline Occlusion 20 troller which receives a signal from the microcontroller 
HR ( bpm ) to activate the pacing circuit to control when the first 87 + 20 88 = 19 
AOP ( mmHg ) 88 + 9 83 - 11 lead and the second lead are activated to pace the heart ; 
Crystal Vol ( mL ) 88 = 12 91 + 12 | and 
Ao Flow ( L / min ) 7 . 0 + 1 . 3 6 . 4 + 1 . 3 an admittance circuit which measures volume regarding RVSP ( mmHg ) 24 . 5 + 3 . 9 23 . 7 = 5 
Gblood ( ms ) the heart in real time in communication with the 73 . 6 + 39 . 8 85 . 0 51 . 1 | microcontroller , the microcontroller controls when the 
Data from n = 6 pigs with 13 electrode positions are shown . admittance circuit measures volume , the microcon heart rate . Aop is systolic right carotid pressure , Crystal Vol is 2D endocardial crystal troller determines from the admittance circuit in real LV volume , Ao Flow is descending thoracic aortic flow , RVSP is right ventricular systolic 
pressure , and Gblood is LV blood conductance derived from epicardial admittance . time whether stroke volume , ejection fraction and end 
I p < 0 . 01 systolic volume regarding the heart are increasing or 
decreasing over time , and changes the pacing circuit ' s 
TABLE 2 operation in real time from the admittance circuit by cycling through pacing algorithms and changing a 
Transient Aortic Occlusion . pacing algorithm which is used by the microcontroller , 
the microcontroller to maximize the stroke volume and Baseline Occlusion ejection fraction and to minimize the end - systolic vol 
HR ( bpm ) 90 = 28 97 = 24 ume . 
AOP ( mmHg ) 86 11 124 + 18 2 . The apparatus of claim 1 including a pacemaker 
Crystal Vol ( mL ) 89 + 21 98 + 22 
Ao Flow ( L / min ) 0 . 7 + 0 . 6 1 6 . 3 + 1 . 2 enclosure and wherein the admittance circuit is disposed in 
RVSP ( mmHg ) 22 . 9 + 4 . 4 23 . 8 + 4 . 4 1 40 the pacemaker enclosure . 
Gblood ( ms ) 53 . 5 + 18 . 6 57 . 4 = 21 . 61 3 . The apparatus of claim 2 wherein the microcontroller is 
disposed in the enclosure and including a wireless transmit Data from n = 11 pigs from 27 electrode positions are shown . ter disposed in the enclosure which transmits a condition Occlusion data were defined at the time of peak AOP . 
HR is heart rate , Aop is systolic right caotid pressure , Crystal Volis 2D endocardial crystal 
LV volume , Ao Flow is descending thoraic aortic flow , RVSP is right ventricular systlic15 
pressure , and Gblood is LV blood conductance derived from epicardial admittance . 
I p < 0 . 01 4 . The apparatus of claim 3 wherein the pacing circuit 
paces each ventricle of the heart separately , where each 
ventricle is paced separately using a variable time delay 
TABLE 3 between a first and a second pace , or takes into account delay 
Pleural Effusion Simulation . 50 between atrial pacing and ventricular pacing , or a combina 
tion thereof . 
Baseline Pleural Effusion 5 . The apparatus of claim 4 including at least a third lead 
for multiple admittance measurements adapted to be in HR ( bpm ) 95 - 19 96 = 21 † 
AOP ( mmHg ) 87 5 86 + 6 electrical communication with the heart . 
Crystal Vol ( mL ) 100 + 29 100 = 27 6 . A method for treating a heart of a patient comprising the 
Gblood ( ms ) 53 . 2 + 33 . 5 52 . 6 + 27 . 8 steps of : 
Data from n = 7 pigs from 54 electrode positions are shown . receiving by a pacing circuit in a pacemaker enclosure in 
pis systolic right carotid pressure , Crystal Vol is 2D endocardial crystal communication with a microcontroller in the pace 
LV volume , and Gblood is LV blood conductance derived from epicardial admittance . maker enclosure a signal from the microcontroller to † p < 0 . 05 , 1 p < 0 . 01 
activate the pacing circuit to control when a first 
Although the invention has been described in detail in the existing lead and a second existing lead of the pace 
foregoing embodiments for the purpose of illustration , it is maker enclosure is activated to pace the heart ; 
to be understood that such detail is solely for that purpose triggering with the microcontroller the first lead in elec 
and that variations can be made therein by those skilled in trical communication with the heart at various times for 
the art without departing from the spirit and scope of the 65 pacing the heart as a function of epicardial admittance 
invention except as it may be described by the following in real time and takes into account delay between atrial 
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a combination of both muscle and blood conductance pacing algorithm which is used by the microcontroller , 
and muscle susceptance components , where the blood the microcontroller to maximize the stroke volume and 
and muscle components are in series and the admit ejection fraction and to minimize the end - systolic vol 
tance has both a real part and an imaginary part ; ume . 
triggering with the microcontroller the second lead in 5 7 . The method of claim 6 including the step of determin 
electrical communication with the heart at different ing stroke volume , and systolic volume , and ejection frac 
times than the various times for pacing the heart so that tion of the heart using epicardial admittance . 
the microcontroller triggers the first lead at different 8 . The method of claim 7 including the step of pacing the 
times from when the microcontroller triggers the sec heart by separately pacing each ventricle of the heart using 
ond lead ; and 10 a variable time delay between a first and a second pace , or 
measuring with an admittance circuit volume regarding ng by taking into account delay between atrial pacing and 
the heart in real time in communication with the ventricular pacing , or by a combination thereof . 
microcontroller , the microcontroller controlling when 9 . The method of claim 8 including the step of re 
the admittance circuit measures volume , the microcon measuring stroke volume , and systolic volume , and ejection 
troller determining from the admittance circuit in real 15 fraction after changing how the heart is paced . 
time whether stroke volume , ejection fraction and end 10 . The method of claim 9 including the step of compar 
systolic volume regarding the heart are increasing or ing the determining step and the re - measuring step , and 
decreasing over time , and changing the pacing circuit ' s repeating them until the stroke volume and ejection fraction 
operation in real time from the admittance circuit by are maximal , and end - systolic volume is minimal . 
cycling through pacing algorithms and changing a * * * * * 
